ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2564

An illustration-based patient-reported outcome measure reveals concealed symptoms in patients with rheumatoid arthritis and the factor contributing to the discrepancy between patient and evaluator global assessments

Mie Fusama1, Hideko Nakahara2, Megumi Okada3, Kayoko Sakagami4, Ikuyo Noguchi5, Harumi Matsumura6, Hiroaki Ito4, Kosaku Oda5, Yoshitaka Shinto3, Kenshi Higami6, Satomi Higami6 and Tetsuya Tomita7, 1Kansai University of International Studies, Miki, Japan, 2Osaka Yukioka College of Health Science, Ibaraki, Osaka, Japan, 3Shinto Orthopaedics and Rheumatology Clinic, Osaka, Japan, 4Infusion Clinic, Osaka, Japan, 5Oda Orthopedic Surgery Rheumatology Clinic, Nishinomiya, Japan, 6Higami Clinic of Rheumatology and Diabetology, Kashihara, Japan, 7Morinomiya University of Medical Sciences, Osaka, Japan

Meeting: ACR Convergence 2025

Keywords: Disease Activity, Patient reported outcomes, quality of life, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (2547–2566) ARP Posters I

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: RA patients frequently encounter challenges in effectively communicating their symptoms to medical professionals. Recently, the “Okomarigoto Sheet” (OS), an illustration-based patient-reported outcome measure for RA patients, was developed and has been widely used in Japan. However, the OS’s correlation with the conventional patient-reported outcome (PRO) has not been sufficiently evaluated. This study aims to investigate whether items on the OS are related to conventional measures of disease activity and PRO, and assess its effectiveness in facilitating patients’ expression of their symptoms.

Methods:  Participants were recruited from four clinics. The OS consists of three symptom scales – morning stiffness duration, the Visual Analogue Scale (VAS) for joint pain and fatigue (0 = none, 100 mm = very severe). Illustrations depicting symptoms in five different situations were also provided for each symptom. Each illustration is scored as follows: no symptoms = 0, mild-moderate symptoms = 1, severe symptoms = 2. The total score of 5 illustrations for each symptom ranges from 0-10, with the total score of whole illustrations ranges from 0 to 30; indicating symptom severity. The correlations between the total illustration score and disease activity and QOL (SF-12) were evaluated. The correlations between patient global assessment (PGA), evaluator global assessment (EGA), and swollen joint count (SJC) and the total score of 5 illustrations for each symptom were also analyzed. Statistical analysis was conducted using Spearman’s rank correlation coefficient.

Results: 80 patients (mean age: 61 years old) responded to the questionnaire. The total score of whole illustrations was positively correlated with DAS28 (rs= 0.538) and CDAI (0.648), and negatively correlated with Physical Component Summary (-0.534) and Mental Component Summary (-0.417) of SF-12. Stiffness duration, pain and fatigue VAS were positively correlated with total score of 5 illustrations for each symptom. Of the patients who scored 0 on stiffness duration, pain and fatigue VAS, 9 patients had symptoms in the illustrations (5 for stiffness; 1 for pain; 4 for fatigue). In addition, PGA was significantly correlated with all of total score of 5 illustrations for each symptom (stiffness: rs=0.551, pain: rs=0.651, fatigue: rs= 0.353, respectively). However, EGA was significantly associated with the total scores of 5 illustrations for stiffness (rs=0.476) and pain (rs=0.449), but not fatigue (rs= 0.164). SJC was also associated with the total scores of 5 illustrations for stiffness (rs=0.263) and pain (rs=0.379), but not fatigue (rs= 0.083).

Conclusion: The illustration-based OS reflected the findings obtained using standard measures of disease activity and QOL. It has also the potential to clarify symptoms that are not adequately captured by VAS. Furthermore, total score of 5 illustrations for fatigue was associated with PGA but not with EGA and SJC. It was reported that EGA is most closely associated with SJC. Therefore, utilizing OS not only clarifies patients’ symptoms in greater detail, but also suggests that fatigue may be one of the factors contributing to the discrepancy between PGA and EGA.


Disclosures: M. Fusama: None; H. Nakahara: None; M. Okada: None; K. Sakagami: None; I. Noguchi: None; H. Matsumura: None; H. Ito: None; K. Oda: None; Y. Shinto: None; K. Higami: None; S. Higami: None; T. Tomita: None.

To cite this abstract in AMA style:

Fusama M, Nakahara H, Okada M, Sakagami K, Noguchi I, Matsumura H, Ito H, Oda K, Shinto Y, Higami K, Higami S, Tomita T. An illustration-based patient-reported outcome measure reveals concealed symptoms in patients with rheumatoid arthritis and the factor contributing to the discrepancy between patient and evaluator global assessments [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/an-illustration-based-patient-reported-outcome-measure-reveals-concealed-symptoms-in-patients-with-rheumatoid-arthritis-and-the-factor-contributing-to-the-discrepancy-between-patient-and-evaluator-glo/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/an-illustration-based-patient-reported-outcome-measure-reveals-concealed-symptoms-in-patients-with-rheumatoid-arthritis-and-the-factor-contributing-to-the-discrepancy-between-patient-and-evaluator-glo/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology